IFN-γ is an acid-labile interferon produced by CD4 and CD8 T lymphocytes as well as activated NK cells. IFN-γ receptors are present in most immune cells, which respond to IFN-γ signaling by increasing the surface expression of class I MHC proteins. This promotes the presentation of antigen to T-helper (CD4+) cells. IFN-γ signaling in antigen-presenting cells, and antigen-recognizing B and T lymphocytes, regulates the antigen-specific phases of the immune response. Additionally, IFN-γ stimulates a number of lymphoid cell functions, including the anti-microbial and anti-tumor responses of macrophages, NK cells, and neutrophils. Human IFN-γ is species-specific and is biologically active only in human and primate cells. Recombinant Human IFN-γ is a 16.8 kDa protein containing 144 amino acid residues.
Immune Interferon, type II interferon, T cell interferon, MAF
MQDPYVKEAE NLKKYFNAGH SDVADNGTLF LGILKNWKEE SDRKIMQSQI VSFYFKLFKN FKDDQSIQKS VETIKEDMNV KFFNSNKKKR DDFEKLTNYS VTDLNVQRKA IHELIQVMAE LSPAAKTGKR KRSQMLFQGR RASQ
≥ 98% by SDS-PAGE gel and HPLC analyses.
Assay #1: Determined by its ability to induce STAT1/STAT2 activation in Human COLO 205 ISRE LUC reporter cells. Assay #2: The ED50 determined by a cytotoxicity assay using HT-29 cells is ≤ 0.05 ng/ml, corresponding to a specific activity of ≥ 2 x 107 units/mg. This product has been tested against the WHO standard. International Unit information can be found here.
Calculated Molecular Weight:
Endotoxin level is < 0.1 ng/ug of protein (< 1 EU/ug)
Not for human use.